@juliaskripkaser @biotechinvstr @syinvesting 1/2
One should always try to comment on company developments critically but fairly.
In terms of content, I also found yesterday's $ZYME presentation somewhat thin. But the deal with $MRK is not bad. Upfront minimal, because it is basically an extension of an existing cooperation,